F98胶质母细胞瘤大鼠模型中[18F]FET与[18F]FAZA PET引导放疗的技术可行性
该研究在F98胶质母细胞瘤大鼠模型中评估了基于[18F]FET或[18F]FAZA PET亚体积推量放疗的可行性与治疗反应。所有治疗组接受T1w MRI引导的20 Gy放疗(5×5 mm2)联合TMZ,两个组分别额外接受5 Gy(1×1 mm2)的PET高摄取区推量。结果显示PET引导亚体积推量技术上可行,但三个治疗组间肿瘤生长无显著差异,仅活动治疗与假治疗间有显著差异。
要点
- PET引导亚体积推量在F98大鼠胶质母细胞瘤中技术可行。
- 三个治疗组间肿瘤生长无显著差异,未见额外获益。
- 仅活动治疗与假治疗间肿瘤生长差异显著。
核心结论
- 本研究显示PET引导的F98胶质母细胞瘤大鼠亚体积推量放疗技术可行,但未发现对肿瘤反应有益处。
研究设计与样本
- F98胶质母细胞瘤细胞接种至大鼠脑内,行T2和增强T1w MRI成像。
- 三个治疗组均接受基于T1w MRI勾画靶区的20 Gy(5×5 mm2)放疗,其中两组分别额外接受5 Gy(1×1 mm2)的[18F]FET或[18F]FAZA PET高摄取区推量。
- 所有治疗组接受腹腔注射TMZ,对照组不接受放疗仅接受对照腹腔注射。
- 对九只大鼠计算两种放疗计划的平均、最小和最大剂量及D90、D50、D2值。
- 基于T1w MRI勾画随访肿瘤体积以评估治疗反应。
主要发现
- 剂量体积直方图比较中,仅D2值发现显著差异。
- 肿瘤生长仅在活动治疗与假治疗之间发现显著差异。
- 三个治疗组之间比较未发现显著差异。
关键数值与推荐
- 放疗剂量:20 Gy(5×5 mm2)基于T1w MRI靶区。
- 额外推量:5 Gy(1×1 mm2)至[18F]FET或[18F]FAZA PET最大摄取区。
- 化疗:所有治疗组接受腹腔注射TMZ。
临床怎么用
- PET引导亚体积推量在动物模型中技术可行,但本研究未显示肿瘤反应获益。
- 需改进啮齿类动物剂量靶向方法并开展针对GB新靶向药物的研究。
局限性
- 未发现PET引导亚体积推量对肿瘤反应的有益效果。
- 研究指出需改进啮齿类动物剂量靶向及开展新靶向药物研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GB) is the most common primary malignant brain tumor. Standard medical treatment consists of a maximal safe surgical resection, subsequently radiation therapy (RT) and chemotherapy with temozolomide (TMZ). An accurate definition of the tumor volume is of utmost importance for guiding RT. In this project we investigated the feasibility and treatment response of subvolume boosting to a PET-defined tumor part. METHOD: F98 GB cells inoculated in the rat brain were imaged using T2- and contrast-enhanced T1-weighted (T1w) MRI. A dose of 20 Gy (5 × 5 mm2) was delivered to the target volume delineated based on T1w MRI for three treatment groups. Two of those treatment groups received an additional radiation boost of 5 Gy (1 × 1 mm2) delivered to the region either with maximum [18F]FET or [18F]FAZA PET tracer uptake, respectively. All therapy groups received intraperitoneal (IP) injections of TMZ. Finally, a control group received no RT and only control IP injections. The average, minimum and maximum dose, as well as the D90-, D50- and D2- values were calculated for nine rats using both RT plans. To evaluate response to therapy, follow-up tumor volumes were delineated based on T1w MRI. RESULTS: When comparing the dose volume histograms, a significant difference was found exclusively between the D2-values. A significant difference in tumor growth was only found between active therapy and sham therapy respectively, while no significant differences were found when comparing the three treatment groups. CONCLUSION: In this study we showed the feasibility of PET guided subvolume boosting of F98 glioblastoma in rats. No evidence was found for a beneficial effect regarding tumor response. However, improvements for dose targeting in rodents and studies investigating new targeted drugs for GB treatment are mandatory.
引用
- Verhoeven J, Bolcaen J, De Meulenaere V, et al. Technical feasibility of [18F]FET and [18F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model. Radiat Oncol. 2019. PMID: 31146757. doi:10.1186/s13014-019-1290-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。